Evidence map›Paper›PMID 34526107›Full record

ArticleBiology of sex differences2021

Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality.

Agne Laucyte-Cibulskiene, Liam J Ward, Thomas Ebert, Giulia Tosti, Claudia Tucci, Leah Hernandez, Alexandra Kautzky-Willer, Maria-Trinidad Herrero, Colleen M Norris, Louise Pilote and 7 more

Open access · goldAbstract read
In one paragraph

Article in Biology of sex differences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Deciphering the impact ofGenes & diseases · 2026
    Article
  4. Article
  5. Microvascular Health as a Key Determinant of Organismal Aging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 5 countries.

Agne Laucyte-Cibulskiene *Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-4020-1467
Liam J Ward *Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-3320-1461
Thomas EbertDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Giulia TostiInstitute of Internal Medicine, Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
Claudia TucciDepartment of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Leah HernandezDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Alexandra Kautzky-WillerDivision of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Maria-Trinidad HerreroClinical and Experimental Neuroscience, Institutes for Aging Research and Bio-Health Research of Murcia, School of Medicine, University of Murcia, Murcia, Spain.
Colleen M NorrisUniversity of Alberta, Faculty of Nursing, Edmonton, AB, Canada.
Louise PiloteDivision of Clinical Epidemiology, Research Institute of McGill University Health Centre, McGill University, Montreal, QC, Canada.
Magnus SöderbergClinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Göteborg, Sweden.
Torkel B BrismarDivision of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Jonaz RipswedenDivision of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Peter StenvinkelDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Valeria Raparelli *University of Alberta, Faculty of Nursing, Edmonton, AB, Canada.
Karolina Kublickiene *Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. karolina.kublickiene@ki.se.ORCID 0000-0002-4841-6836
GOING-FWD Consortium
Karolinska Institutet · SEKarolinska University Hospital · SEAgostino Gemelli University Polyclinic · ITAlberta Health Services · CAAstraZeneca (Sweden) · SELund University · SEMcGill University Health Centre · CAMedical University of Vienna · ATUniversidad de Murcia · ESUniversity of Alberta · CAUniversity of Florence · IT

Funding

Austrian Science Fund FWF I 4209
6 · The paper itself

Abstract

backgroundSex differences are underappreciated in the current understanding of cardiovascular disease (CVD) in association with chronic kidney disease (CKD). A hallmark of CKD is vascular aging that is characterised, amongst others, by; systemic inflammation, microbiota disbalance, oxidative stress, and vascular calcification-features linked to atherosclerosis/arteriosclerosis development. Thus, it is the necessary to introduce novel biomarkers related to athero-/arteriosclerotic damage for better assessment of vascular ageing in patients CKD. However, little is known about the relationship between uraemia and novel CVD biomarkers, such as growth differentiation factor-15 (GDF-15), cartilage glycoprotein-39 (YKL-40) and matrix metalloproteinase-9 (MMP-9). Therefore, we hypothesise that there are sex-specific relationships between GDF-15, YKL-40, MMP-9 levels in end-stage kidney disease (ESKD) patients in relation to gut microbiota, vascular calcification, inflammation, comorbidities, and all-cause mortality.

methodsESKD patients, males (n = 151) and females (n = 79), not receiving renal replacement therapy were selected from two ongoing prospective ESKD cohorts. GDF-15, YKL-40 and MMP9 were analysed using enzyme-linked immunosorbent assay kits. Biomarker levels were analysed in the context of gut microbiota-derived trimethylamine N-oxide (TMAO), vascular calcification, inflammatory response, oxidative stress, comorbidities, and all-cause mortality.

resultsIncreased GDF-15 correlated with higher TMAO in females only, and with higher coronary artery calcification and IL-6. In females, diabetes was associated with elevated GDF-15 and MMP-9, whilst males with diabetes only had elevated GDF-15. No associations were found between biomarkers and CVD comorbidity. Deceased males and females had higher GDF-15 concentrations (p = 0.01 and p < 0.001, respectively), meanwhile only YKL-40 was increased in deceased males (p = 0.02).

conclusionsIn conclusion, in males GDF-15 and YKL-40 were related to vascular calcification, inflammation, and oxidative stress, whilst in females GDF-15 was related to TMAO. Increased levels of YKL-40 and GDF-15 in males, and only GDF-15 in females, were associated with all-cause mortality. Our findings suggest that sex-specific associations of novel CVD biomarkers have a potential to affect development of cardiovascular complications in patients with ESKD.

Indexed as

Kidney Failure, ChronicMatrix Metalloproteinase 9Chitinase-3-Like Protein 1FemaleGrowth Differentiation Factor 15HumansMaleProspective StudiesCHI3L1 protein, humanChitinase-3-Like Protein 1GDF15 protein, humanGrowth Differentiation Factor 15Matrix Metalloproteinase 9MMP9 protein, humanBiomarkersCalcificationCardiovascular diseaseChronic kidney diseaseEnd stage kidney diseaseTMAOUraemia

Identifiers

PMID34526107
PMCPMC8444580
OpenAlexW3199067987

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.